Surufatinib — a novel oral agent for neuroendocrine tumours
Surufatinib — a novel oral agent for neuroendocrine tumours
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, thymic and lung neuroendocrine tumours.
Alternative Titles
Full title
Surufatinib — a novel oral agent for neuroendocrine tumours
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2456431276
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2456431276
Other Identifiers
ISSN
1759-5029
E-ISSN
1759-5037
DOI
10.1038/s41574-020-00439-0
